Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(β-amino esters)

Biomaterials

Volumn 33, Issue 27, 2012, Pages 6495-6506

  Yin, Qi ^a   Shen, Jianan ^a   Chen, Lingli ^a   Zhang, Zhiwen ^a   Gu, Wangwen ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Multidrug resistance; P glycoprotein; Poly( amino esters); RNA; Survivin

Indexed keywords

AMINO ESTERS; CELL LINES; COMPLEX NANOPARTICLES; DIFFERENT MECHANISMS; DOXORUBICIN; HUMAN BREAST CANCER; HUMAN CANCER; MICHAEL ADDITION REACTIONS; MULTIDRUG RESISTANCE; NONVIRAL; P-GLYCOPROTEIN; RNA INTERFERENCE; SINGLE VECTORS; SURVIVIN; SYNERGISTIC EFFECT; TETRAETHYLENEPENTAMINE; TUMOR CELLS; TUMOR VOLUMES;

ADDITION REACTIONS; CELL CULTURE; CHEMOTHERAPY; DISEASES; ESTERIFICATION; ESTERS; GENES; TUMORS;

RNA;

AZAMETHONIUM; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; POLY[BIS(2 HYDROXYLETHYL)DISULFIDE DIACRYLATE BETA TETRAETHYLENEPENTAMINE]; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MALE; MICHAEL ADDITION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; CATIONS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; GENE TRANSFER TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; OXIDATION-REDUCTION; P-GLYCOPROTEIN; POLYMERS; QUATERNARY AMMONIUM COMPOUNDS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

MUS;

EID: 84863575657     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.05.039     Document Type: Article

References (32)

1. Shi Z., Tiwari A.K., Patel A.S., Fu L.W., Chen Z.S. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res 2011, 71:3735-3738.
2. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporter in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010, 10:147-156.
3. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9:665-674.
4. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L.R., Chu X.Y., et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010, 9:215-236.
5. Li Y.L., Duan X., Jing L.H., Yang C.H., Qiao R.R., Gao M.Y. Quantum dot-antisense oligonucleotide conjugates for multifunctional gene transfection, mRNA regulation, and tracking of biological processes. Biomaterials 2011, 32:1923-1931.
6. Wang F.H., Zhang D.R., Zhang Q., Chen Y.X., Zheng D.D., Hao L.L., et al. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance. Biomaterials 2011, 32:9444-9456.
7. Schmitt U., Abou El-Ela A., Guo L.J., Glavinas H., Krajcsi P., Baron J.M., et al. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm 2006, 113:787-801.
8. Dönmez Y., Akhmetova L., I.Şeri ö.D., Kars M.D., Gündüz U. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemother Pharm 2011, 67:823-828.
9. Modok S., Mellor H.R., Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 2006, 6:350-354.
10. He Q.J., Gao Y., Zhang L.X., Zhang Z.W., Gao F., Ji X.F., et al. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 2011, 32:7711-7720.
11. Cho H.J., Yoon H.Y., Koo H., Ko S.H., Shim J.S., Lee J.H., et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials 2011, 32:7181-7190.
12. Vergara D., Bellomo C., Zhang X., Vergaro V., Tinelli A., Lorusso V., et al. Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine 2011, 10.1016/j.nano.2011.10.01.
13. Abbasi M., Lavasanifar A., Uluda H. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med Res Rev 2011, 10.1002/med.20244.
14. Gao Y., Chen L.L., Zhang Z.W., Chen Y., Li Y.P. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials 2011, 32:1738-1747.
15. Xiong X.B., Uludag H., Lavasanifar A. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. Biomaterials 2009, 30:242-253.
16. Xue H.Y., Wong H.L. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 2011, 32:2662-2672.
17. Wu Y.H., You Y., Chen Z.C., Zou P. Reversal of drug resistance by silencing survivin gene expression in acute myeloid leukemia cells. Acta Biochim Pol 2008, 55:673-680.
18. Vivas-Mejia P.E., Rodriguez-Aguayo C., Han H.D., Shahzad M.M.K., Valiyeva F., Shibayama M., et al. Silencing Survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin Cancer Res 2011, 17:3716-3726.
19. Pecot C.V., Calin G.A., Coleman R.L., Lopez-Berestein G., Sood A.K. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011, 11:59-67.
20. Tzenga S.Y., Guerrero-Cázaresb H., Martineza E.E., Sunshinea J.C., Quiñones-Hinojosab A., Green J.J. Non-viral gene delivery nanoparticles based on poly(β-amino esters) for treatment of glioblastoma. Biomaterials 2011, 32:5402-5410.
21. Ramasubramanian A., Shiigi S., Lee G.K., Yang F. Non-viral delivery of inductive and suppressive genes to adipose-derived stem cells for osteogenic differentiation. Pharm Res 2011, 28:1328-1337.
22. Shim M.S., Kwon Y.J. Dual mode polyspermine with tunable degradability for plasmid DNA and siRNA delivery. Biomaterials 2011, 32:4009-4020.
23. Jere D.J., Cho C.S. Biodegradable polymer-mediated sh/siRNA delivery for cancer studies. Methods Mol Biol 2010, 623:243-269.
24. Yin Q., Gao Y., Zhang Z.W., Zhang P.C., Li Y.P. Bioreducible poly (β-amino esters)/shRNA complex nanoparticles for efficient RNA delivery. J Control Release 2011, 151:35-44.
25. Fu Y., Kao W.J. In situ forming poly(ethylene glycol)-based hydrogels via thiol-maleimide Michael-type addition. J Biomed Mater Res A 2011, 98:201-211.
26. He S.M., Li R., Kanwar J.R., Zhou S.F. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem 2011, 18:439-481.
27. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70.
28. Bien S., Rimmbach C., Neumann H., Niessen J., Reimer E., Ritter C.A., et al. Doxorubicin-induced cell death requires cathepsin B in HeLa cells. Biochem Pharmacol 2010, 80:1466-1477.
29. Bian K., Fan J., Zhang X., Yang X.W., Zhu H.Y., Wang L., et al. MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett 2012, 586:804-809.
30. Mahmoudi M., Azadmanesh K., Shokrgozar M.A., Journeay W.S., Laurent S. Effect of nanoparticles on the cell life cycle. Chem Rev 2011, 111:3407-3432.
31. Du B.Y., Song W., Bai L., Shen Y., Miao S.Y., Wang L.F. Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines. Chemotherapy 2012, 58:44-51.
32. Mena S., Rodriguez M.L., Ortega A., Priego S., Obrador E., Asensi M., et al. Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1. J Transl Med 2012, 10:8-20.